Category Archives: Biotech

Roche Ups the Stakes on Personalized Medicine

By Guest Blogger | Published: February 1, 2012
By Patricia Van Arnum, Pharmaceutical Technology. Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry. Several pharmaceutical majors continue to invest in this emerging field as evident by Roche’s $5.7-billion bid last week for Illumina, a provider of gene-sequencing tools and related analytics.
Also posted in Europe, Global, Guest Blog | Tagged , , | Leave a comment

Putting the M Back in M&A

By Jennifer Ringler | Published: December 13, 2011
Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Also posted in Agency Insight, Deals, FDA | Tagged , , , | Leave a comment

The HCR Taxman Cometh

By Guest Blogger | Published: September 13, 2011
By Tom Norton As the country struggles with the current economic malaise, and the pharmaceutical industry enters into yet another difficult quarter of “trying to make the numbers,” one matter that I doubt many Rx execs are thinking about today is the HCR Taxman.  That’s too bad.  They probably should.  That’s because he’s coming for the [...]
Also posted in Advertising, Agency Insight, Corporate Responsibility, Strategy, compliance | Comments closed

Florida Builds on Biotech Industry

By Jennifer Ringler | Published: May 23, 2011
While the biotechnology industry has weakened across the U.S., Florida has seen a 21 percent jump in the number of biotech companies since 2008 and a surge in investment, according to the University of Florida. Updated numbers from the Florida BioDatabase, maintained by the University of Florida’s Sid Martin Biotechnology Incubator. in Alachua, show 29 new [...]
Posted in Biotech | Tagged , , | Leave a comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

By Ben Comer | Published: May 18, 2011
Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, [...]
Also posted in Agency Insight, Emerging Markets, Europe, Strategy | Tagged , , | 1 Comment